HOME >> BIOLOGY >> NEWS
Promising cell protein may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye, according to researchers at the University of Pennsylvania and Temple University.

The researchers, led by Mina Massaro-Giordano, M.D., of the University of Pennsylvania's Scheie Eye Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute for Cancer Research at Temple University (www.shro.org), published their study,

"Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells," in Cell Death and Differentiation (www.nature.com/cdd).

They recently presented their findings at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Florida, which was attended by over 10,000 researchers.

PAI-2, in either extracellular or secreted form, is a multifunctional protein that plays a role in cell differentiation, in prevention of programmed cell death, in the regulation of cell proliferation, in the inhibition of microbial proteinases and in the protection against stromal degradation.

High levels of the PAI-2 protein are associated with a good prognosis in breast cancer, small cell lung, ovarian cancer, and inhibition of metastasis. PAI-2 also plays a role in inflammation on the surface of the eye.

In their study, the Penn and Temple researchers demonstrate for the first time an interaction between PAI-2 and the tumor suppressing gene Rb2/p130 in the nucleus of the epithelial cells in the cornea and conjunctiva.

According to the researchers, this interaction with Rb2/p130 and chromatin modeling enzymes may affect how PAI-2 is expressed. <
'"/>

Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-7476
Temple University
16-May-2006


Page: 1 2

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising anti-TB compound finally can be synthesized with ease
7. Promising results in the battle against incurable ALS muscle disease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Penn researchers discover how key protein stops inflammation
10. UCF research links proteins, stem cells and potential Alzheimers treatment
11. Teamwork between 2 key proteins necessary for normal development and regulation of red blood cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/28/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... January 28, ... ... complex problems for life sciences companies and government agencies, announced that the firm ... hubs in the country. Tunnell’s Cambridge office will be in the Cambridge Innovation ...
(Date:1/27/2020)... ... January 27, 2020 , ... ... Thorne is a noted investor, tech entrepreneur, and former senior management consultant at ... of Broadline Capital, the global alternative investment firm. , “Chris Thorne has ...
(Date:1/24/2020)... ... 2020 , ... Worldwide Business with kathy ireland® has announced an ... President of Sales and Marketing Jeff Maier to discuss their innovative technology, High-Speed Vibration ... Jan. 26, 2020 at 5:30 p.m. EST and internationally on Bloomberg Television on Saturday, ...
Breaking Biology News(10 mins):
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant ... surgery industry at two recent North American investor forums specializing in medical advancements. ... Medical Technologies & Diagnostics Forum on November 21, 2019 in New York City, ...
(Date:1/10/2020)... N.J. (PRWEB) , ... January 09, 2020 , ... ... Study of Drug Development establishes benchmarks for the vendor qualification process, a ... Impact Report, the process volume and complexity of the vendor qualification process creates ...
(Date:1/7/2020)... ... January 07, 2020 , ... Absolute Antibody ... the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in ... rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to ...
(Date:12/31/2019)... ... December 31, 2019 , ... ... pharmaceutical product development lab in Maryland. Emphasis will be in expanding ... expanded capabilities, Vici Health Sciences will be well positioned to meet the growing ...
Breaking Biology Technology:
Cached News: